OLT1177’s specific inhibition of NLRP3 inflammasomes offers a promising therapeutic approach to prevent the release of pro-inflammatory factors IL-1β and IL-18, potentially benefiting the treatment of allergic diseases. Here, IL1B is linked to allergic disease.